Assessing cognitive function in cancer patients
Goals of work
Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments.
Materials and methods
Cancer patients (n=31) who had received adjuvant chemotherapy within 2 years underwent cognitive evaluation on three occasions. Fluent English speakers (n=20) completed the High Sensitivity Cognitive Screen (HSCS), the computer-based Headminder and CogHealth, and the Functional Assessment of Cancer Therapy-cognitive function (FACT-COG) questionnaire. Patients not fluent in English (NESB) (n=11) performed CogHealth and Headminder.
The patients were aged 31–65 years, and 94% were women with breast cancer. At baseline, 6 of 20 (30%) had moderate–severe cognitive impairment on HSCS, 17 of 31 (55%) had scores greater than one standard deviation (SD) below the mean for normative data in one to two of three domains on Headminder, and on CogHealth, 8 of 31 (26%) were greater than one SD below the mean in at least two of six domains. A large practice effect was seen for the HSCS, with moderate–severe cognitive impairment decreasing from 30 to 5% between the first and second assessment. On FACT-COG, 9 of 19 patients (47%) rated their cognition as greater than one SD below that of a pre-chemotherapy breast cancer control group, with impact on quality of life greater than one SD below for 10 of 19 (53%) patients. No correlation was seen between objective cognitive testing and the FACT-COG.
CogHealth and Headminder were suitable for NESB patients. The HSCS is not recommended for longitudinal studies with short intervals between testing due to practice effect. There is poor correlation between the patients’ perception of their cognitive impairment and the objective tests.
KeywordsCognitive impairment Neuropsychological assessment Adjuvant chemotherapy
- 1.van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuy, ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218CrossRefPubMedGoogle Scholar
- 2.Wieneke MH, Dienst DE (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61–66Google Scholar
- 5.Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMedGoogle Scholar
- 9.Bornstein R (1994) Methodological and conceptual issues in the study of cognitive change in HIV infection. In: Grant I, Martin A (eds) Neuropsychology of HIV Infection. Oxford Univ. Press, New York, pp 146–160Google Scholar
- 20.Miller EN, Wilkie FL (1994) Computerized testing to assess cognition in HIV-positive individuals. In: Grant I, Martin A (eds) Neuropsychology of HIV infection. Oxford Univ. Press, New York, pp 161–175Google Scholar
- 25.Wagner LI, SJ, Cella D, Donninger N (2003) Chemotherapy-related cognitive deficits: A qualitative examination of patients and providers. Ann Behav Med 25:S056Google Scholar
- 26.Fan H, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms and cognitive function in women following adjuvant chemotherapy for breast cancer: one and two year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032CrossRefPubMedGoogle Scholar
- 27.Falleti MG, Maruff P, Collie A, Darby DG (2006) Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test–retest intervals. J Clin Exp Neuropsychol (in press)Google Scholar